EIDD-1931 for COVID-19
c19early.org
COVID-19 Treatment Clinical Evidence
COVID-19 involves the interplay of 500+ viral and host proteins and factors, providing many therapeutic targets.
c19early analyzes 6,000+ studies for 220+ treatments—over 17 million hours of research.
Only three high-profit early treatments are approved in the US.
In reality, many treatments reduce risk,
with 25 low-cost treatments approved across 163 countries.
-
Naso/
oropharyngeal treatment Effective Treatment directly to the primary source of initial infection. -
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
-
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
-
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
-
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
-
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
-
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
-
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
-
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.
EIDD-1931 may be beneficial for
COVID-19 according to the studies below.
COVID-19 involves the interplay of 500+ viral and host proteins and factors providing many therapeutic targets.
Scientists have proposed 11,000+ potential treatments.
c19early.org analyzes
220+ treatments.
We have not reviewed EIDD-1931 in detail.
, Boesenbergia rotunda
–Derived Phytochemicals as Potent Inhibitors of SARS‐CoV‐2 Papain–Like Protease (PLpro): Insights From Molecular Docking and Dynamic Simulation, Scientifica, doi:10.1155/sci5/1695824
The papain‐like protease (PLpro) of SARS‐CoV‐2 plays fundamental roles in its replication, and its mechanistic inhibition can impede the virus’s replication and infection. Most Plpro inhibitors identified thus far are chemically synthesized and subject to numerous restrictions regarding stability and adverse side effects. Nevertheless, the inhibitors of those compounds can be replaced with natural, selective PLpro inhibitors that are highly stable and have minimal adverse effects. Since ancient times, extracts of Boesenbergia rotunda (L.) Mansf. have been recognized for their antiviral and other properties. Consequently, the objective of the investigation was to investigate the inhibitory activity of B. rotunda extract compounds against the virus, with the intention of inhibiting PLpro’s signaling function in its replicative pathway, as a result, preventing viral infections. Molecular docking was initially suggested to evaluate the level of binding affinity among 57 natural compounds identified from B. rotunda to the desired protein. The results of this computational analysis have additionally been compared against molnupiravir, which has been addressed experimentally for its interacting efficiency towards the PLpro receptor protein of SARS‐CoV‐2 lately. This comparison indicates that the proposed dietary compounds have a significantly noticeable interaction efficiency regarding binding efficiency and other energetic contributions. Furthermore, the structure of PLpro was significantly influenced by compounds in MD‐simulation experiments that were validated through some standard analyses, such as RMSF (root mean square fluctuation), RMSD (root mean square deviation), solvent accessible surface area, radius of gyration, MolSA, and PSA. The most promising three phytochemicals that could be established as an antiviral curative option against SARS‐CoV‐2 infection have been identified through computational approaches: rubranine, boesenbergin B, and panduratin A. The results of our computational investigation indicate that our proposed medications require clinical experimentation; consequently, they may be a superior treatment against SARS‐CoV‐2 viral infection.